Sign in
Taking people in United StatesPhase 2

Donor Stem Cell Transplant Using Treosulfan for Blood Cancers

Tests a donor stem cell transplant with treosulfan-based treatment in people with blood cancers.

Key facts

Who runs it
Fred Hutchinson Cancer Center
Where
Seattle, United StatesSee the site
Trial code
Registry title
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Status
Recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
25 Jan 2021
Expected to end
12 Mar 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Cyclophosphamide
  • Cyclosporine
  • Filgrastim
  • Fludarabine
  • Mycophenolate Mofetil
  • Mycophenolate Sodium
  • Total-Body Irradiation
  • Treosulfan
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Echocardiography Test
  • Biospecimen Collection
  • Computed Tomography
  • Positron Emission Tomography
Record updated
29 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with certain blood cancers who need a donor stem cell transplant from a half-matched family donor. They must be in remission or partial response, and be fit enough for the transplant.

Age
6 months and older
Sex
All sexes
Disease stage
Acute leukemia in complete remission; chronic myeloid leukemia (not refractory blast crisis); chronic myelomonocytic leukemia; myelodysplastic syndromes; lymphomas in complete or partial response, with the stage depending on the lymphoma type.
Earlier treatment
First chronic phase chronic myeloid leukemia: at least one tyrosine-kinase inhibitor that failed or was not tolerated. Low-grade lymphoma: progressed after two treatment regimens. A previous donor stem cell transplant must have been at least 3 months before joining, unless the graft failed.
Biomarker or test result
Donor and patient must share at least 5 of 10 HLA loci. Anti-donor antibodies (DSA) must be below an MFI of 5000 after desensitization treatment.

Main reasons for not taking part

  • Active, uncontrolled, life-threatening infection
  • Another cancer with expected survival under 75% at 5 years
  • Pregnant or breastfeeding
  • Known allergy to treosulfan, fludarabine or cyclophosphamide
  • Another investigational drug within 30 days before joining

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • Acute leukemia (AL) that includes acute myeloid leukemia (AML) / acute lymphoblastic leukemia (ALL) / mixed phenotype leukemia (MPAL) in complete morphological remission (CR) with or without detectable minimal residual disease (MRD); complete morphological remission is defined by the presence of less than 5% of detectable blasts in bone marrow specimen, evaluated per standard of care. Patients with documented CR but without hematologic recovery since last chemotherapy are considered eligible to the study
  • Chronic myelogenous leukemia (CML), except refractory blast crisis. To be eligible in first chronic phase, patients must have failed or be intolerant to at least one tyrosine-kinase inhibitor
  • Chronic myelomonocytic leukemia (CMML)
  • Myelodysplastic syndromes (MDS)
  • Lymphoblastic, Burkitt's and other high-grade lymphoma in any complete (CR) or partial (PR) response; CR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
  • Low grade lymphoma (chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL], marginal zone lymphoma, follicular lymphoma) progressed after two treatment regimens, in CR/PR; For CLL/SLL, CR and PR are defined according to: International Workshop on CLL (iwCLL) guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL; CR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
  • Large cell lymphoma in > second CR (CR2)/ >= PR2; CR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
  • Mantle cell lymphoma, lymphoplasmacytic lymphoma and prolymphocytic leukemia may be eligible after initial therapy if in CR/PR; CR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification; For prolymphocytic leukemia (PLL), CR is defined as a normalization of lymphadenopathies (long-axis diameter < 1 cm) and splenomegaly (< 13 cm), absence of constitutional symptoms, PLL cells < 5% in bone marrow and circulating lymphocytes count < 4 x 10\^9/L. Patients without hematopoietic recovery are considered eligible to the study. PR is defined as a decrease of >= 30% of the sum of lymphadenopathies' long-axis diameters, a decrease of >= 50% in spleen vertical length beyond normal from baseline, peripheral blood (PB) lymphocytes =< 30 x 10\^9/L (and a decrease of >= 50% from baseline)
  • Hodgkin Lymphoma in > CR2/PR2; CR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
  • Subjects must be >= 6 months old
  • Karnofsky >= 70 or Eastern Cooperative Oncology Group (ECOG) 0-1 (for adults)
  • Lansky score >= 50 (for children)
  • Adequate cardiac function defined as absence of decompensated congestive heart failure or uncontrolled arrhythmia AND left ventricular ejection fraction >= 40% or shortening fraction > 22%
  • Adequate pulmonary function defined as absence of oxygen (O2) requirements and one of the following:; Diffusion capacity of the lung for carbon monoxide (DLCO) corrected >= 70% mm Hg; DLCO corrected between 60% - 69% mm Hg and partial pressure of oxygen (pO2) >= 70 mm Hg; DLCO corrected between 50% - 59% mm Hg and pO2 >= 80 mm Hg Pediatric patients unable to perform pulmonary function tests must have O2 saturation >= 92% on room air. May not be on supplemental oxygen
  • Total bilirubin < 2 x upper limit of normal (ULN) unless felt to be related to Gilbert's disease or hemolysis
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
  • Alkaline phosphatase =< 5 x ULN
  • Creatinine < 2.0 mg/dl (adults) or estimated creatinine clearance > 40 ml/min (pediatrics); All adults with a creatinine > 1.2 or a history of renal dysfunction must have estimated creatinine clearance > 40 ml/min
  • If recent mold infection, e.g., aspergillus, must be cleared by infectious disease to proceed
  • Patients who have undergone prior allogeneic hematopoietic cell transplant are eligible, but the prior transplant must have been performed at least 3 months prior to enrollment, unless in case of graft failure from the prior transplant
  • Written and signed informed consent
  • DONOR: Donors must be haploidentical relatives of the patients. Donor-recipient compatibility will be tested through HLA typing at high resolution for the HLA loci (-A, -B, -C, -DRB1, -DQB1). Donor and recipient should share at least 5/10 HLA loci
  • DONOR: Age >= 12 years
  • DONOR: Weight >= 40 Kg
  • DONOR: Ability of donors younger than 18 years of age to undergo apheresis without use of a vascular access device. Vein check must be performed and verified by an apheresis nurse prior to arrival
  • DONOR: Donor must meet selection criteria as defined by the Foundation of the Accreditation of Cell Therapy (FACT) and will be screened per the American Association of Blood Banks (AABB) guidelines
  • DONOR: In case of more available haploidentical donors, selection criteria should include, in this order:; For cytomegalovirus (CMV) seronegative recipients, a CMV seronegative donor; Red blood cell compatibility; Red blood cell (RBC) cross match compatible; Minor ABO incompatibility; Major ABO incompatibility

Who cannot take part

  • Dosing with another investigational agent within 30 days prior to entry in the study
  • Central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy and/or cranial radiation prior to initiation of conditioning (day -6)
  • DONOR: Since detection of anti-donor-specific-antigen antibodies (anti-DSA) is associated with higher graft rejection rate, patients will be screened for anti-DSA pre-transplant. Patients with DSA mean fluorescent intensity (MFI) < 5000 after desensitization treatment, will be considered eligible to participate in the study. The first 10 subjects enrolled in the trial will be DSA-negative
  • Active, uncontrolled, life-threatening viral, bacterial or fungal infection requiring treatment at time of conditioning regiment administration and transplantation
  • Presence of a malignancy other than the one for which the transplant is being performed, with an expected survival less than 75% at 5 years
  • Known hypersensitivity to treosulfan, fludarabine or cyclophosphamide
  • Pregnant or breastfeeding

Where in United States

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, United StatesContact: Phuong Vo, MDTaking people

About the trial

What the trial wants to find out

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.

The 2 groups in the trial

  • Arm A (high dose treosulfan)Treatment being tested

    Patients receive high dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation on day -1 and allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3-4. Beginning on day 5, patients receive cyclosporine IV BID or TID over 1-2 hours or PO (after 3 months, in the absence of GVHD, cyclosporine tapering will start by 5-10% per week, until drug withdrawal at 6 months post-transplant). Beginning on day 5, patients also receive mycophenolate sodium PO TID or mycophenolate mofetil IV or PO TID until day 35 (may be continued if active GVHD is present). Beginning on day 5, patients also receive filgrastim until the absolute neutrophil count is \> 1,000/uL for 3 consecutive days. Additionally, patients undergo bone marrow aspiration and biopsy, and echocardiography at baseline and blood sample collection and CT or PET/CT on study.

    Treatment: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Filgrastim, Fludarabine, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Treosulfan, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Biospecimen Collection, Computed Tomography, and Positron Emission Tomography

  • Arm B (low dose treosulfan)Treatment being tested

    Patients receive low dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation and allogeneic hematopoietic stem cell transplantation, and receive cyclophosphamide, cyclosporine, mycophenolate sodium or mycophenolate mofetil, and filgrastim as in Arm A. Additionally, patients undergo bone marrow aspiration and biopsy, and echocardiography at baseline and blood sample collection and CT or PET/CT on study.

    Treatment: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Filgrastim, Fludarabine, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Treosulfan, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Biospecimen Collection, Computed Tomography, and Positron Emission Tomography

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen
Plain-language title
Donor Stem Cell Transplant Using Treosulfan for Blood CancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
29 May 2026